Sientra, Inc. announced that the U.S. Food and Drug Administration (FDA) approved the Low Plus Profile Projection Breast Implant for breast augmentation in women at least 22 years old, and for women of all ages undergoing breast reconstruction. This product will be commercially available for board-certified and board-eligible plastic surgeons in the United States in late July 2022. More than 500,0001 women in the U.S. chose to have a breast augmentation or revision procedure last year and, according to recent statistics from the American Society for Aesthetic Plastic Surgery, breast augmentation including revision procedures increased 41% from 2020 to 20211, making it the highest revenue-generating procedure for plastic surgeons.

Providing plastic surgeons with a wide range of implant sizes and profiles allows them tap into their artistry and individualize each patient's results to meet their unique goals and preferences.